Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone with or without Bevacizumab in Platinum-Resistant Ovarian Cancer
NCT03093155Phase 2Completed
- Sponsor
- Yale University
- Start
- Apr 2017
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Yale University. Primary endpoint: Progression-Free Survival up to 37 months. Started Apr 2017; status: completed.
02
Drugs
bevacizumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03093155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093155.